809 related articles for article (PubMed ID: 32760400)
1. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
Saleh R; Toor SM; Sasidharan Nair V; Elkord E
Front Immunol; 2020; 11():1469. PubMed ID: 32760400
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer.
Sasidharan Nair V; Toor SM; Taha RZ; Shaath H; Elkord E
Clin Epigenetics; 2018 Aug; 10(1):104. PubMed ID: 30081950
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?
Ali MA; Matboli M; Tarek M; Reda M; Kamal KM; Nouh M; Ashry AM; El-Bab AF; Mesalam HA; Shafei AE; Abdel-Rahman O
Immunotherapy; 2017 Jan; 9(1):99-108. PubMed ID: 28000527
[TBL] [Abstract][Full Text] [Related]
5. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.
Dai E; Zhu Z; Wahed S; Qu Z; Storkus WJ; Guo ZS
Mol Cancer; 2021 Dec; 20(1):171. PubMed ID: 34930302
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoints in the tumor microenvironment.
Toor SM; Sasidharan Nair V; Decock J; Elkord E
Semin Cancer Biol; 2020 Oct; 65():1-12. PubMed ID: 31265893
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients.
Elashi AA; Sasidharan Nair V; Taha RZ; Shaath H; Elkord E
Oncoimmunology; 2019; 8(2):e1542918. PubMed ID: 30713804
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
Perrier A; Didelot A; Laurent-Puig P; Blons H; Garinet S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708698
[TBL] [Abstract][Full Text] [Related]
11. Tumor immune checkpoints and their associated inhibitors.
Gao Z; Ling X; Shi C; Wang Y; Lin A
J Zhejiang Univ Sci B; 2022 Oct; 23(10):823-843. PubMed ID: 36226537
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic modulation in cancer immunotherapy.
Gallagher SJ; Shklovskaya E; Hersey P
Curr Opin Pharmacol; 2017 Aug; 35():48-56. PubMed ID: 28609681
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach.
Kgatle MM; Boshomane TMG; Lawal IO; Mokoala KMG; Mokgoro NP; Lourens N; Kairemo K; Zeevaart JR; Vorster M; Sathekge MM
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921181
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications.
Yin J; Gu T; Chaudhry N; Davidson NE; Huang Y
Front Immunol; 2023; 14():1325615. PubMed ID: 38268926
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
Terranova-Barberio M; Thomas S; Munster PN
Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K
Front Immunol; 2021; 12():652160. PubMed ID: 33859645
[TBL] [Abstract][Full Text] [Related]
17. Combining epigenetic and immune therapy to overcome cancer resistance.
Gomez S; Tabernacki T; Kobyra J; Roberts P; Chiappinelli KB
Semin Cancer Biol; 2020 Oct; 65():99-113. PubMed ID: 31877341
[TBL] [Abstract][Full Text] [Related]
18. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.
Liu M; Zhou J; Chen Z; Cheng AS
J Pathol; 2017 Jan; 241(1):10-24. PubMed ID: 27770445
[TBL] [Abstract][Full Text] [Related]
19. Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future.
Pan M; Zhao H; Jin R; Leung PSC; Shuai Z
Front Immunol; 2023; 14():1156212. PubMed ID: 37090741
[TBL] [Abstract][Full Text] [Related]
20. Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors.
Liang Y; Wang L; Ma P; Ju D; Zhao M; Shi Y
Front Immunol; 2023; 14():1308264. PubMed ID: 38077327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
